New Data on Genzyme MS Drug Shows Improvement in Disability
Summary
Last November, Genzyme revealed that in a late-stage trial, the drug reduced relapse rates and the risk of long-term disability, and today, at the annual meeting of the American Academy of Neurology, the company shed more light on that data.The data released today also included observations from imaging tests that tracked patches of inflammation in the central nervous systems of the MS patients in the trial.Sibold, who joined Genzyme about five months ago from Avanir Pharmaceuticals, previously worked in Biogen Idec’s (NASDAQ: BIIB) neurology business.We see a lot of potential to help patients.” Patients on Genzyme’s drug did experience more infections and thyroid issues than those taking interferon, but most of the adverse events were mild to moderate, and they were easily manageable, the company said in a statement.Genzyme plans to file for FDA approval of alemtuzumab by the end of this quarter, and it will be reviewed in an expedited manner by the agency, which has granted it “fast track” status.